All In Biotech

Drug Trial Radar · NCT03181399

Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)

Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D)

Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Apr 18, 2018

Primary completion

Sep 10, 2023

Study completion Sep 10, 2023

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Jun 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 24 months, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in addition to IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuropsychological and neurological performance indices in children and adults genetically diagnosed with G1D receiving a regular diet at enrollment.

Conditions

  • GLUT1DS1
  • Epilepsy
  • Glut1 Deficiency Syndrome 1, Autosomal Recessive
  • Glucose Metabolism Disorders
  • Glucose Transport Defect
  • Glucose Transporter Type 1 Deficiency Syndrome
  • Glucose Transporter Protein Type 1 Deficiency Syndrome

Interventions

  • TriheptanoinDrug

    . Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Neuropsychological Score of Sustained AttentionTime frame: Change post 6 months of treatment
  2. Neuropsychological Score of Sustained AttentionTime frame: Change after 3 months off treatment
  3. Neuropsychological Score of Working Memory Index Scale (WMI)Time frame: Change post 6 months of treatment
  4. Neuropsychological Score of Working Memory Index Scale (WMI)Time frame: Change after 3 months off-treatment
  5. Neuropsychological Score of Processing Speed Index (PSI)Time frame: Change post 6 months of treatment
  6. Neuropsychological Score of Processing Speed Index (PSI)Time frame: Change after 3 months off-treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas Southwestern Medical Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.